An international standard Indonesian pharmaceutical company, Dexa Group, is committed to exporting its products to Europe. Through its subsidiary, Ferron Par Pharmaceuticals, Dexa Group signed a cooperation agreement with Allgen Pharmaceutical & Generic B.V from the Netherlands and Bioton S.A from Poland. The signing of this collaboration was carried out at the 2022 Trade Expo Indonesia (TEI) event at ICE BSD, Tangerang, Wednesday (19/10). In TEI 2022, PT Ferron Par Pharmaceuticals is one of the companies that sign contracts with exporters. President Director of PT Ferron Par Pharmaceuticals, Benny Sutisna Suwarno said the export of pharmaceutical products to the Netherlands proves that PT Ferron Par Pharmaceuticals is able to increase international market confidence by producing domestic products that are guaranteed both safety and quality. "This export also shows that pharmaceutical products from Indonesia are able to compete with similar products from various continents, including Europe as the host," said Benny at BSD Tangerang, Wednesday (19/10).
Benny explained, Dexa Group has penetrated the market into the Netherlands since 2018 through its Glucient SR product. Before entering the Netherlands, the product was already accepted by the British market and received a positive response. Dexa Group then saw trade opportunities to other European countries. "We hope that in the Netherlands, we can also develop, starting next year so that we can expand to other countries. Our partner from Allgen also has the same ambition, also wants to penetrate other European countries for our products to Luxembourg, Belgium,” said Benny. On the same day, PT Ferron Par Pharmaceuticals also signed a partnership with a Polish company, Bioton S.A at the Indonesia - Central & Eastern European (INACEE) Business Forum 2022 event. Bioton S.A is a leading company for biotechnology related to the treatment of type II Diabetes Mellitus. Commercial Director, PT Ferron Par Pharmaceuticals, Johannes Suthya said that after entering the UK market, Ferron saw an opportunity in Poland. Based on World Bank data, Poland's diabetes prevalence in 2011 was 9%, far above the UK's 5.2%. "This opportunity was used by Ferron to enter the Polish market through antidiabetic drugs with the trademark Avamina SR. Avamina SR is a metformin product from Indonesia that first entered the Polish market," said Johannes. Also present was the Director General of National Export Development Didi Sumedi who also added that the signing of the trade contract was carried out by 14 countries. Didi also hopes that the transaction target of this TEI event can be achieved. "The value is USD 1.19 billion, there are 14 countries. There are about maybe 10 types of products. The implementation of TEI is expected to achieve the target of USD 10 billion," he explained.
